Literature DB >> 21160987

Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma.

Yao-Jun Zhang1, Min-Shan Chen.   

Abstract

Radiofrequency ablation (RFA), one of the most advanced loco-regional ablative therapeutic methods, is widely utilized in the treatment of hepatocellular carcinoma (HCC). Because of its minimal invasiveness and high efficacy, RFA has been regarded as a curative therapy as alternative to surgical resection and liver transplantation. It brings new hope and a new treatment pattern for small HCC. In this article, we summarize the important role of RFA in the treatment of small HCC according to our clinical experience over six years. The prognosis of small HCC after RFA is comparable to that of surgical resection but with higher safety, less complications, wider applicability, and good long-term survival. RFA will play a more and more important role in the clinical treatment of small HCC.

Entities:  

Keywords:  Complication; Hepatectomy; Hepatocellular carcinoma; Prognosis; Radiofrequency ablation; Recurrence; Therapy

Year:  2010        PMID: 21160987      PMCID: PMC2999277          DOI: 10.4254/wjh.v2.i4.146

Source DB:  PubMed          Journal:  World J Hepatol


  25 in total

1.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

2.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy.

Authors:  Toshiya Shibata; Yuji Iimuro; Yuzo Yamamoto; Yoji Maetani; Fumie Ametani; Kyo Itoh; Junji Konishi
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

4.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

5.  Hepatic resection for hepatocellular carcinoma. An audit of 343 patients.

Authors:  E C Lai; S T Fan; C M Lo; K M Chu; C L Liu; J Wong
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

6.  Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe.

Authors:  Z-W Peng; H-H Liang; M-S Chen; Y-J Zhang; J-Q Li; Y-Q Zhang; W Y Lau
Journal:  Eur J Surg Oncol       Date:  2007-09-11       Impact factor: 4.424

7.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

8.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

Review 9.  Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future.

Authors:  W Y Lau; Thomas W T Leung; Simon C H Yu; Stephen K W Ho
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

10.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.

Authors:  Bao-Quan Cheng; Chong-Qi Jia; Chun-Tao Liu; Wei Fan; Qing-Liang Wang; Zong-Li Zhang; Cui-Hua Yi
Journal:  JAMA       Date:  2008-04-09       Impact factor: 56.272

View more
  2 in total

1.  Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.

Authors:  Zhitao Chen; Tielong Wang; Chuanbao Chen; Xitao Hong; Jia Yu; Yihao Ma; Yiwen Guo; Changjun Huang; Xiaoshun He; Weiqiang Ju; Maogen Chen
Journal:  J Oncol       Date:  2021-10-19       Impact factor: 4.375

2.  Green-Synthesized Silver Nanoparticle-Assisted Radiofrequency Ablation for Improved Thermal Treatment Distribution.

Authors:  Zhannat Ashikbayeva; Arman Aitkulov; Timur Sh Atabaev; Wilfried Blanc; Vassilis J Inglezakis; Daniele Tosi
Journal:  Nanomaterials (Basel)       Date:  2022-01-27       Impact factor: 5.076

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.